ISSN: 0443-511
e-ISSN: 2448-5667
Usuario/a
Idioma
Herramientas del artículo
Envíe este artículo por correo electrónico (Inicie sesión)
Enviar un correo electrónico al autor/a (Inicie sesión)
Tamaño de fuente

Open Journal Systems

Caracterización epidemiológica de la COVID-2019 en población obstétrica mexicana: estudio de cohorte / Epidemiological characterization of COVID-2019 in Mexican pregnant women: a cohort study

María Guadalupe Berumen-Lechuga, Carlos José Molina-Pérez, Luis Rey García-Cortés, José Esteban Muñoz-Medina, Martín Rosas-Peralta, María de los Ángeles Dichi-Romero, Yazmín Jocelyn Julián-Hernández, Alan Suresh Vázquez-Rasposo, Silvia Palomo-Piñón

Resumen


Resumen

Introducción:  la COVID-19 en el embarazo puede incrementar el riesgo de complicaciones debido a los cambios cardiorrespiratorios e inmunológicos propios de la gestación.

Objetivo: reportar la caracterización epidemiológica de la COVID-19 en población obstétrica mexicana.

Material y métodos: estudio de cohorte en embarazadas con prueba positiva para COVID-19 que fueron seguidas hasta la resolución del embarazo y un mes después.

Resultados: 758 mujeres embarazadas fueron incluidas en el análisis. La media de edad en las madres fue 28.8 ± 6.1 años; la mayoría trabajadoras 497 (65.6%) y de origen urbano (482, 63.6%); el grupo sanguíneo más común fue O 458 (63.0%); 478 (63.0%) fueron primigestas, y más del 25% padecía comorbilidades; las semanas de gestación promedio al contagio fueron 34.4 ± 5.1 semanas; solo 170 gestantes (22.4%) recibieron vacunación; la vacuna más frecuente fue BioNTech Pfizer (96, 60%); no hubo eventos adversos graves atribuibles a la vacunación. La edad gestacional media al nacer fue de 35.4 ± 5.2 semanas; el 85% de los embarazos se interrumpieron por cesárea; la complicación más frecuente fue la prematurez con 406 (53.5%), seguida de preeclampsia con 199 (26.2%); hubo 5 casos de muerte materna y 39 casos de muerte perinatal.

Conclusiones: la COVID-19 en el embarazo aumenta el riesgo de parto prematuro, preeclampsia y muerte materna. Al menos en esta serie la vacunación contra COVID-19 no mostró riesgo para las mujeres embarazadas y sus recién nacidos.

 

Abstract

Background: COVID-19 in pregnancy can increase the risk of complications due to the cardiorespiratory and immunological changes typical of pregnancy.

Objective: To report the epidemiological characterization of COVID-19 in Mexican pregnant women.

Material and methods: Cohort study on pregnant women with a positive COVID-19 test, which were followed until delivery and one month later.

Results: 758 pregnant women were included in the analysis. Mothers’ mean age was 28.8 ± 6.1 years; the majority were workers 497 (65.6%) and with an urban origin (482, 63.6%); the most common blood group was O with 458 (63.0%); 478 (63.0%) were nulliparous women and more than 25% had some comorbidities; the average gestation weeks at infection were 34.4 ± 5.1 weeks; only 170 pregnant women (22.4%) received vaccination; the most frequent vaccine was BioNTech Pfizer (96, 60%); there were no serious adverse events attributed to vaccination. The mean gestational age at delivery was 35.4 ± 5.2 weeks; 85% of pregnancies were cesarean section; the most frequent complication was prematurity (406, 53.5%), followed by preeclampsia (199, 26.2%); there were 5 cases of maternal death and 39 cases of perinatal death.

Conclusions: COVID-19 in pregnancy increases the risk of preterm birth, preeclampsia, and maternal death. Vaccination against COVID-19 in this series showed no risk for pregnant women and their newborns.


Palabras clave


COVID-19; Vacunas COVID-19; Embarazo / COVID-19; COVID-19 Vaccines; Pregnancy

Texto completo:

PDF

Referencias


 

Chang L, Yan Y, Wang L. Coronavirus Disease 2019: Coronaviruses and Blood Safety. Transfus Med Rev. 2020 Apr;34(2):75-80. doi: 10.1016/j.tmrv.2020.02.003.

 

Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020 Mar 17;9(1):29. doi: 10.1186/s40249-020-00646-x.

 

Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020 Apr;87(4):281-286. doi: 10.1007/s12098-020-03263-6.

 

Dashraath P, Wong JLJ, Lim MXK, Lim LM, Li S, Biswas A, Choolani M,et al. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. Am J Obstet Gynecol. 2020 Jun;222(6):521-531. doi: 10.1016/j.ajog.2020.03.021.

 

Schwartz DA, Graham AL. Potential Maternal and Infant Outcomes from (Wuhan) Coronavirus 2019-nCoV Infecting Pregnant Women: Lessons from SARS, MERS, and Other Human Coronavirus Infections. Viruses. 2020 Feb 10;12(2):194. doi: 10.3390/v12020194.  

 

D'Antonio F, Sen C, Mascio DD, Galindo A, Villalain C, Herraiz I, Arisoy R, et al.  On the behalf of the World Association of Perinatal Medicine working group on coronavirus disease 2019. Maternal and perinatal outcomes in high compared to low risk pregnancies complicated by severe acute respiratory syndrome coronavirus 2 infection (phase 2): the World Association of Perinatal Medicine working group on coronavirus disease 2019. Am J Obstet Gynecol MFM. 2021 Jul;3(4):100329. doi: 10.1016/j.ajogmf.2021.100329.

 

Blumberg D, Sridhar A, Lakshminrusimha S, Higgins RD, Saade G. COVID-19 Vaccine Considerations during Pregnancy and Lactation. Am J Perinatol. 2021 May;38(6):523-528. doi: 10.1055/s-0041-1726390.

 

Wainstock T, Yoles I, Sergienko R, Sheiner E. Prenatal maternal COVID-19 vaccination and pregnancy outcomes. Vaccine. 2021 Oct 1;39(41):6037-6040. doi: 10.1016/j.vaccine.2021.09.012.

 

Bookstein Peretz S, Regev N, Novick L, Nachshol M, Goffer E, Ben-David A, et al. Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine. Ultrasound Obstet Gynecol. 2021 Sep;58(3):450-456. doi: 10.1002/uog.23729.

 

Male V. SARS-CoV-2 infection and COVID-19 vaccination in pregnancy. Nat Rev Immunol. 2022 May;22(5):277-282. doi: 10.1038/s41577-022-00703-6.

 

De Rose DU, Salvatori G, Dotta A, Auriti C. SARS-CoV-2 Vaccines during Pregnancy and Breastfeeding: A Systematic Review of Maternal and Neonatal Outcomes. Viruses. 2022 Mar 5;14(3):539. doi: 10.3390/v14030539..

 

Lumbreras-Marquez MI, Fields KG, Campos-Zamora M, Rodriguez-Bosch MR, Rodriguez-Sibaja MJ, Copado-Mendoza DY, et al.  A forecast of maternal deaths with and without vaccination of pregnant women against COVID-19 in Mexico. Int J Gynaecol Obstet. 2021 Sep;154(3):566-567. doi: 10.1002/ijgo.13788.

 

Verduzco Rodríguez L, González Puebla E, Manffrini Madrid F, López Ariza B. Dímero-D en las diferentes etapas de la toxemia del embarazo. Estudio piloto [D-dimer in different stages of pregnancy toxemia. A pilot study]. Ginecol Obstet Mex. 1998 Feb;66:77-80.

 

Wirestam L, Pihl S, Saleh M, Wetterö J, Sjöwall C. Plasma C-Reactive Protein and Pentraxin-3 Reference Intervals During Normal Pregnancy. Front Immunol. 2021 Aug 2;12:722118. doi: 10.3389/fimmu.2021.722118.

 

Di Toro F, Gjoka M, Di Lorenzo G, De Santo D, De Seta F, Maso G, et al. Impact of COVID-19 on maternal and neonatal outcomes: a systematic review and meta-analysis. Clin Microbiol Infect. 2021 Jan;27(1):36-46. doi: 10.1016/j.cmi.2020.10.007.

 

Mullins E, Evans D, Viner RM, O'Brien P, Morris E. Coronavirus in pregnancy and delivery: rapid review. Ultrasound Obstet Gynecol. 2020 May;55(5):586-592. doi: 10.1002/uog.22014.

 

Yu N, Li W, Kang Q, Xiong Z, Wang S, Lin X, Liu Y, et al. Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study. Lancet Infect Dis. 2020 May;20(5):559-564. doi: 10.1016/S1473-3099(20)30176-6.

 

Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020 Mar 7;395(10226):809-815. doi: 10.1016/S0140-6736(20)30360-3.

 

Di Mascio D, Khalil A, Saccone G, Rizzo G, Buca D, Liberati M, et al. Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2020 May;2(2):100107. doi: 10.1016/j.ajogmf.2020.100107.

 

WAPM (World Association of Perinatal Medicine) Working Group on COVID-19. Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection. Ultrasound Obstet Gynecol. 2021 Feb;57(2):232-241. doi: 10.1002/uog.23107.

 

Leaños-Miranda A, Inova Campos-Galicia, Méndez-Aguilar F, Molina-Pérez CJ, Ramírez-Valenzuela KL, Sillas-Pardo LJ, et al. Lower circulating angiotensin II levels are related to the severity of preeclampsia and its risk as disclosed by a specific bioassay. Medicine (Baltimore). 2018 Sep;97(39):e12498. doi: 10.1097/MD.0000000000012498.

 

Jamieson DJ, Rasmussen SA. An update on COVID-19 and pregnancy. Am J Obstet Gynecol. 2022 Feb;226(2):177-186. doi: 10.1016/j.ajog.2021.08.054.

 

Papageorghiou AT, Deruelle P, Gunier RB, Rauch S, García-May PK, Mhatre M, Usman MA, et al. Preeclampsia and COVID-19: results from the INTERCOVID prospective longitudinal study. Am J Obstet Gynecol. 2021 Sep;225(3):289.e1-289.e17. doi: 10.1016/j.ajog.2021.05.014.


Enlaces refback

  • No hay ningún enlace refback.